Anna Nicole Smith Possibly Died of Flu 'Cytokine Storm'

ST. LOUIS--(EON:Enhanced Online News)--GenoMed® (Pink Sheets:GMED), a Next Generation Disease Management company, announced today that Anna Nicole Smith possibly died of a "cytokine storm" associated with the flu. GenoMed has obtained excellent results against the "cytokine storm" for the past five years, using already-existing blood pressure pills present in most drugstores on earth. Ms. Smith's death may have been preventable.

Ms. Smith's attorney, Ron Rale, told The Associated Press that he had talked to her on Tuesday or Wednesday, and she had flu symptoms and a fever.

GenoMed recognized before anyone else that what kills healthy people from a viral disease is the "cytokine storm" their own body creates to fight the virus. For five years, GenoMed has been running free clinical trials for West Nile virus encephalitis, regular influenza, and avian influenza ("bird flu"). Its treatments are the subject of pending patents.

Unfortunately, the public health authorities have been completely uncooperative. For example, the CDC tried to shut down GenoMed's WNV trial in June 2004. And the WHO has yet to respond to GenoMed about the bird flu. Instead, the WHO has urged governments to stockpile Tamiflu at the cost of billions of dollars, even though Tamiflu is known to have a 10% viral resistance rate. Since GenoMed targets the host's response, rather than trying to kill the virus, there should be no viral resistance.

Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "We've found a novel approach to viral disease for the general population. If the CDC and WHO hadn't ignored us for the past 5 years, Anna Nicole Smith might have heard about us, used our approach to reduce her flu symptoms, and still be alive. Every drugstore on earth carries the drugs we use. And they're a lot safer than aspirin."

About GenoMed

Patients are encouraged to download GenoMed's approach to avian influenza from its website, www.genomed.com. GenoMed estimates that it can already save 10% of healthcare costs and extend life by 5 years. Patients are encouraged to contact Dr. Moskowitz ([e-mail]) about joining GenoMed's Clinical Outcomes Improvement Program (COIP®).

Safe Harbor Statement

This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.